What condition may be associated with Zofran exposure during pregnancy?

Zofran (ondansetron) is an anti-nausea medication commonly used to treat nausea and vomiting during pregnancy, particularly due to morning sickness. Studies have suggested a potential association between Zofran exposure during pregnancy and an increased risk of congenital heart defects (CHD) in the offspring.

The exact mechanism for this association is not fully understood, but it is hypothesized that interventions during critical periods of fetal development may influence heart formation. Although the overall risk remains low, the data indicates a noteworthy correlation warranting further examination and caution by healthcare providers when prescribing this medication to pregnant individuals.

Other conditions listed, such as developmental dysplasia of the hip, cleft lip and palate, and neonatal adaptation disorder, have not been consistently linked to Zofran exposure based on current evidence. While cleft lip and palate and neonatal adaptation disorder are also potential concerns with other medications or exposures during pregnancy, the specific association with congenital heart defects has garnered significant attention in the context of Zofran use. This highlights the importance of understanding potential risks when prescribing treatments for pregnant individuals experiencing nausea and vomiting.